Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Lymphoid 2Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Xanthogranuloma, Juvenile 1Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Hepatoblastoma 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 31Magnetic Resonance Spectroscopy 29Specimen Handling 17Radiation 12Radiotherapy 11Biopsy 11Bevacizumab 10Nivolumab 9X-Rays 7Radiosurgery 7Nuclear Medicine Department, Hospital 7Carboplatin 7Lomustine 6Cyclophosphamide 6Vincristine 5Phantoms, Imaging 5Cisplatin 5ulixertinib 4trametinib 4pembrolizumab 4erdafitinib 4binimetinib 4abemaciclib 4Irinotecan 4Ipilimumab 4Etoposide 4Aminolevulinic Acid 4AZD 6244 4pertuzumab 3lutetium Lu 177 dotatate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tazemetostat × CNS × 30 days × Clear all
NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡